INDUCTION OF TUMOR SPECIFIC CYTOTOXIC T LYMPHOCYTES IN PROSTATE CANCER USING PROSTATIC ACID PHOSPHATASE DERIVED HLA-A2402 BINDING PEPTIDE

This publication has 22 references indexed in Scilit:

• Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
  Journal of Clinical Oncology, 2000
• Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide
  The Prostate, 1998
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
  Nature Medicine, 1998
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
  Nature Medicine, 1998
• A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
  The Journal of Experimental Medicine, 1996
• Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3
  International Journal of Cancer, 1995
• A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3
  European Journal of Immunology, 1994
• Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
  The Journal of Experimental Medicine, 1994
• A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
  The Journal of Experimental Medicine, 1992
• Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. IV. Anti-Androgen Treated Patients
  Journal of Urology, 1989